Two Alzheimer’s drugs under-development have failed in their clinical trials. Bapineuzumab and Solanezumab, the two drugs, have been unsuccessful in helping those patients suffering with mild to moderate dementia.

The research, published in the Jan. 23 issue of the New England Journal of Medicine, states that two novel drugs failed in improving the cognitive function of patients.

On Wednesday, scientists claimed that the failure of the two drugs has been a lesson for them in developing more future drugs. The important fact is that the drugs suffered a setback for the first time in 2012, smashing the hopes of millions of people whose loved ones were suffering with dementia.

Stephen Salloway, Prof. of neurology and psychiatry at Brown University's Warren Alpert Medical School, said: “The biggest disappointment from this trial was that if we had shown benefit with drug like bapi, it would give people hope that Alzheimer's is treatable disease that we can slow it down”.

Heather Snyder, director of medical and scientific operations for the Alzheimer's Association, said that these drugs could prove more effective in preventing Alzheimer instead of treating it.